Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Announces A New Suite of Ion Torrent Oncomine Immune Repertoire Assays Designed to Detect Potentially Malignant Clones of T-Cells and B-Cells

07/19/2021 | 08:00am EDT

Thermo Fisher Scientific announced a new suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T-cells and B-cells, which play a key role in the immune response system. Using proprietary Ion AmpliSeq technology, the new pan-clonality assays target multiple parts of the B- and T-cell immune receptors using a single reaction with ultra-high sensitivity, thereby increasing the probability of malignant clone detection and decreasing the time to results. Detection of distinct receptor DNA sequences can inform diagnostic, prognostic and therapy development studies in the progression of lymphoid cancers including leukemias, lymphomas and diseases such as multiple myeloma. Using next-generation sequencing (NGS) technology, detection sensitivity can be increased compared to traditional testing methods such as flow cytometry or qPCR. One of the challenges of current NGS-based immune repertoire analysis has been the need to run multiple secondary tests due to the high test-failure rates of a typical single NGS assay. The new Oncomine pan-clonality assays overcome this challenge by uniquely targeting multiple parts of the receptor to reduce the need for secondary tests and increase the probability that a single assay can detect a potentially malignant clone. Thermo Fisher's new suite of immune repertoire assays are available on the Ion GeneStudio S5 System and feature integrated analysis and data visualization tools that simplify the interpretation of results for laboratories and healthcare professionals.


© S&P Capital IQ 2021
All news about THERMO FISHER SCIENTIFIC
09/17US Stocks Drop as Large-Cap Techs Lose Luster; Consumer Sentiment Disappoints..
MT
09/17THERMO FISHER SCIENTIFIC : Provides Consensus-Topping Adj. EPS, Revenue Guidance..
MT
09/17Equities Decline Midday as Bond Yields Jump While Downbeat Consumer Sentiment..
MT
09/17MIDDAY REPORT : US Stocks Decline as Bond Yields Jump While Downbeat Consumer Se..
MT
09/17Thermo Fisher On Pace for Record High Close -- Data Talk
DJ
09/17THERMO FISHER SCIENTIFIC : Regulation FD Disclosure (Form 8-K)
PU
09/17THERMO FISHER SCIENTIFIC INC. : Regulation FD Disclosure (form 8-K)
AQ
09/16THERMO FISHER SCIENTIFIC : FDA Approves Tissue-Based NGS Companion Diagnostic fo..
AQ
09/16THERMO FISHER SCIENTIFIC : Automated Enzyme Analyzers Streamline Enzyme Assay Ap..
PU
09/16Thermo Fisher Scientific Inc. Announces Automated Enzyme Analyzers Streamline..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 36 059 M - -
Net income 2021 7 164 M - -
Net Debt 2021 15 367 M - -
P/E ratio 2021 33,1x
Yield 2021 0,16%
Capitalization 235 B 235 B -
EV / Sales 2021 6,94x
EV / Sales 2022 7,06x
Nbr of Employees 80 000
Free-Float 89,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 596,80 $
Average target price 586,33 $
Spread / Average Target -1,76%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors